VTX002 for Ulcerative Colitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if taking VTX002 regularly as a tablet is safe and effective for people with moderate to severe ulcerative colitis. The goal is to see if it can reduce symptoms and heal the gut lining.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Snehal Naik, PhD
Principal Investigator
Ventyx Biosciences, Inc
Are You a Good Fit for This Trial?
This trial is for people who've had moderate to severe ulcerative colitis (UC) for at least 3 months. They must have active UC confirmed by a special camera test called endoscopy. People with other types of colitis, severe widespread colitis, Crohn's disease, or a history of certain abnormal connections in their intestines can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Treatment
Participants receive VTX002 Dose A, Dose B, or placebo for 13 weeks, including 7 days of titration followed by 12 weeks of treatment at the assigned dose
Long-Term Extension (LTE) Treatment
Participants continue treatment with VTX002 for up to 39 weeks
Open-Label Extension (OLE) Treatment
Participants may opt into continuation of treatment with VTX002 for up to 143 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VTX002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oppilan Pharma Ltd
Lead Sponsor